At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 11 enrolled
Drug / intervention
Fosaprepitant 150 mgdrug
Likely dose
Fosaprepitant 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Fosaprepitant on Motor Evoked and Somatosensory Evoked Potentials Under General Anesthesia
In Brief
A Phase 4 clinical trial evaluating Fosaprepitant 150 mg for Postoperative Nausea. Completed, enrolled 11 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if intravenous fosaprepitant can interfere with nervous system monitoring signals in patients having surgery under general anesthesia. This medication has numerous effects on the sensory nerve transmission which can theoretically have effects on the ability to accurately measure somatosensory evoked potentials.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostoperative Nausea
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedJun 2017
Enrollment StartJan 2018
Primary CompletionJan 2020
TodayJul 2026
First PostedJun 23, 2017
Enrollment StartJan 1, 2018
Primary CompletionJan 31, 2020
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 9.0 years ago
Interventions
Fosaprepitant 150 mgdrug
Antiemetic used to prevent nausea and vomiting after general anesthesia.